You are here
Request for Proposals (RFP) Executive Summary
ASSESSING OCULAR BLOOD FLOW IN GLAUCOMA
Optic Nerve Head (ONH) Blood Flow
There are many scientific papers that have acknowledged that decreased perfusion is generally observed in the eyes of glaucoma patients. Part of the lack of acceptance of this as a potential biomarker is the challenge of identifying which vascular beds should be measured and which measures of flow are most relevant. This challenge, coupled with the technical limits of the available technologies (depth of relevant vessels) has led to controversial positions on the clinical relevance of this biomarker. The desired outcome of research is to establish a direct link between specific measures of blood flow in specific vascular beds and the clinical manifestation of glaucoma.
Key Requirements for Successful RFP Bidders
In depth research in ocular blood flow instrumentation would be engaged to develop standard testing procedures for assessing ONH blood flow and that elucidate the relationship of blood flow to visual function. Initial testing may involve preclinical animal models using a battery of instrumentation however emphasis on clinical evaluation of ocular blood flow with the optimized assessment tools is the desired culmination of this research. Desired capabilities and expertise of bidders to this project include:
- Preferably, access to and expertise in multiple ocular blood flow technologies; depending on the strength of the proposal, consideration will be given to bidders with access and expertise in a single technology.
- Expertise in physiology/pathophysiology of ocular perfusion of the optic nerve and retina and proven publication record in this area.
- Prior experience in clinical research in glaucoma and current access to glaucoma patients.
- Expertise in visual function assessment modalities.
- Prior experience or access to expertise in preclinical glaucoma models relevant for ocular perfusion is desirable but not essential.
- The relationship between perfusion of ONH and progression of optic neuropathy due to glaucoma will be established.
- Scientific rationale is developed for acceptance of this as a mechanism or outcome biomarker that confirms measurable functional effects resulting from modulation of ONG perfusion by pharmacological intervention or ocular disease.
Time to Solve the Problem
The estimated timeframe is within 3 years. Please provide a best estimate of time in the proposal.
Request for Proposal (RFP) Due Date
All final proposals must be submitted no later than August 31, 2007.
Submitting a Proposal
If you are interested in submitting a proposal to address the above therapeutic area topic, please complete the following informational template and send it to: [email protected]
- Ophthalmology - RFI (PDF)
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.